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Summary
Objective: To analyze the gene expression profile of human fetal cartilage by expressed sequence tags (ESTs).
Methods: A human fetal cartilage (8–12 weeks) cDNA library was constructed using the λ ZAP Express vector. ESTs were obtained by partial
sequencing of cDNA clones. The basic local alignment search tool algorithm was used to compare all generated ESTs to known sequences.
Results: A total of 13,155 ESTs were analyzed, of which 8696 ESTs (66.1%) matched known genes, 53 ESTs (0.4%) were putatively novel
(with no match) and the rest matched other ESTs, genomic DNA and repetitive sequences. Importantly, we identified 2448 unique known
genes through non-redundancy analysis of the known gene matches, which were then functionally categorized. The tissue specificity of this
library was reflected by its EST profile of the extracellular matrix (ECM) proteins. Collagens were the major transcripts, representing 68.5%
of the ECM proteins. Proteoglycans were the second most abundant, constituting 9.5%. Collagen type II was the most abundant gene of all.
Glypican 3, decorin and aggrecan were the major transcripts of proteoglycans. Many genes involved in cartilage development were
identified, such as insulin-like growth factor-II, its receptor and binding proteins, connective tissue growth factor and fibroblast growth factors.
Proteases and their regulatory factors were also identified, including matrix metalloprotease 2 and tissue inhibitor of metalloproteinase 1.
Conclusions: The EST approach is an effective way of characterizing the genes expressed in cartilage. These data represent the most
extensive molecular information on human fetal cartilage to date. The availability of this information will serve as a basis for further research
to identify genes that are essential in cartilage development.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
During fetal development, articular cartilage is initially
derived from the interzone of mesenchymal condensations.
The mesenchymal cells cluster together and synthesize
matrix proteins. The tissue is recognized as cartilage when
the accumulation of matrix separates the cells, which are
spherical in shape and are now called chondrocytes.
During cartilage formation and growth, chondrocytes
proliferate rapidly and synthesize large volumes of matrix.
Prior to skeletal maturity, chondrocytes are at their highest
level of metabolic activity. As skeletal maturation is
reached, the rate of chondrocyte metabolic activity and cell
division declines. After completion of skeletal growth, most
chondrocytes do not divide but do continue to synthesize
matrix proteins such as collagens, proteoglycans and other
non-collagenous proteins1,2.
Long-term maintenance of the structural integrity of
mature cartilage relies on the proper balance between
matrix synthesis and degradation. Chondrocytes maintain
matrix equilibrium by responding to chemical and mech-
anical stimuli from their environment. Appropriate and
effective chondrocyte responses to these stimuli are essen-
tial for cartilage homeostasis. Disruption of homeostasis
through either inadequate anabolic activity or excessive
catabolic activity can result in cartilage degradation and
osteoarthritis (OA)3.
OA is the most common chronic joint disease. It is
characterized by progressive degeneration and eventual
loss of cartilage. Currently, there is no effective therapy
that will alter the course of OA. We believe that further
advances in preventing, modifying or curing OA disease
critically depends, at least in part, on a thorough under-
standing of the molecular mechanisms underlying the in-
itiation and regulation of cartilage development. In addition,
fetal cartilage represents a self-constructing state in which
chondrocytes are proliferating and metabolically active.
Thus, understanding the genes involved in these activities
will help us identify the key genes relevant to cartilage
repair in disease.
One effective and rapid way of characterizing gene
expression patterns in a given tissue is through large-
scale partial sequencing of its cDNA library to generate
ESTs. This approach has provided both quantitative and
qualitative information on gene expression in a variety of
tissues and cells4–7. Since cDNA libraries represent gene
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transcription in the cells of the tissue used to construct the
library, gene expression profiles generated by random
sampling and sequencing can be used for detailed genetic-
level comparison between developmental, normal and
pathological states of the tissue examined.
The purpose of the current study was to use an EST-
based approach to analyze the gene expression profile
of human fetal articular cartilage. A human fetal carti-
lage cDNA library was constructed and 13,155 ESTs
obtained from the library were subsequently analyzed and
characterized.
Methods
RNA EXTRACTION AND CDNA LIBRARY CONSTRUCTION
Human fetal femoral cartilage samples were grossly
dissected within an hour from aborted fetuses (8–12
weeks) to make sure that there was no visual contamina-
tion of other tissues and stored immediately in liquid
nitrogen. Approximately 20 samples were collected and
pooled for total RNA isolation using TRIzol reagent
(GIBCO/BRL). Purity and integrity of RNA were assessed
by absorbance at 260/280 nm and agarose gel electro-
phoresis. The poly (A)+ RNA fraction was isolated by
oligo-dT cellulose chromatography (Pharmacia), and
3–5 µg poly (A)+ RNA was used to construct a cDNA library
in the λ ZAP Express vector (Stratagene). First-strand
cDNA was synthesized with an Xho I-oligo (dT) adapter-
primer in the presence of 5′-methyl dCTP. After second-
strand synthesis and ligation of EcoRI adapters, the cDNA
was digested with Xho I, resulting in cDNA flanked by
EcoRI sites at the 5′-ends and Xho I sites at the 3′-ends.
Digested cDNAs were size-fractionated in Sephacryl S-500
spin columns (Stratagene), and then ligated into the λ ZAP
Express vector predigested with EcoRI and Xho I. The
resulting DNA/cDNA concatomers were packaged using
Gigapack Gold packaging extracts. After titration, aliquots
of primary packaging mix were stored in 7% DMSO at
−80°C as primary library stocks, and the rest were
amplified to establish stable library stocks8.
LARGE-SCALE SEQUENCING OF CDNA INSERTS
From the amplified λ ZAP Express library, phage plaques
were plated at a density of 200–500 pfu/150 mm plate onto
Escherichia coli XL1-blue MRF′ lawn with IPTG/X-gal for
color selection. Plaques were picked into 75 µl suspension
media buffer (100 mM NaCl, 10 mM MgSO4, 1 mM Tris, pH
7.5, 0.02% gelatin). Phage elutes (5 µl) were used for PCR
reactions (50 µl total volume) with 125 µmol/l of each dNTP
(Pharmacia), 10 pmol each of modified T3 (5′-GCCAAGC
TCGAAATTAACCCTCACTAAAGGG-3′) and T7 (5′-CCA
GTGAATTGTAATACGACTCACTATAGGGCG-3′) primers,
and 2 U of Taq DNA polymerase (Pharmacia). Reactions
were cycled in a DNA Thermal Cycler (Perkin–Elmer)
[denaturation at 95°C for 5 min, followed by 30 cycles of
amplification (94°C, 45 s; 55°C, 30 s; 72°C, 3 min) and
a terminal isothermal extension (72°C, 3 min)]. Agarose
gel electrophoresis was used to assess the presence
and purity of inserts. PCR products (2 µl, 100–150 ng) were
then subjected to DNA sequencing reactions using
Amplicycle (Perkin–Elmer) sequencing kit and 5 pmol of
Cy5-labeled, modified forward T3 primer (5′-GAAATTA
ACCCTCACTAAAGGG-3′). Sequencing reactions were
incubated at 94°C for 2 min, followed by 20 cycles of 94°C,
30 s; 50°C, 15 s; and 72°C, 1 min; and 15 cycles of 94°C,
30 s; and 72°C for 1 min. Reactions were stopped by
adding 0.5 vol loading buffer (95% formamide, 20 mmol/l
EDTA, 10 mg/ml blue dextran). Sequencing reactions were
then electrophoresed with A.L.F. Express DNA Sequencers
(Pharmacia)8.
DATA ACQUISITION AND ANALYSIS
All generated EST sequences were compared to the
non-redundant Genbank/EMBL/DDBJ and dbEST data-
bases using the basic local alignment search tool (BLAST)
algorithm9. A minimum value of P1010 and nucleotide
sequence identity >95% were required for assignment of
putative identities for the ESTs. Known gene matches are
the ones matching either well-defined known genes or
hypothetical proteins in the public nucleotide and protein
databases. EST matches are those sequences that did not
match known genes and matched ESTs in the EST data-
base. DNA sequences are the ones that had no match in
known genes and ESTs, but matched genomic sequences.
Novel ESTs are those that did not match any sequences in
the databases. Non-redundant analysis of the known gene
matches is a process where the number of ESTs with the
same gene match is counted and the gene is recorded as
one unique gene. This was done with the help of Unigene,
Entrez and PubMed at the National Center for Biotechnol-
ogy Information (NCBI) site (http://www.ncbi.nlm.nih.gov/).
Unigene accession number was used wherever applicable.
Relative gene expression frequency was calculated by
dividing the number of EST copies for each gene by the
total number of ESTs analyzed. Functional characterization
of ESTs with known gene matches was made according to
the categories described by Hwang et al.5.
Results
GENERAL INFORMATION OF THE ESTS
A total of 13,155 ESTs were analyzed from the human
fetal cartilage cDNA library (excluding mitochondria and
vector sequences). Of these, 8696 ESTs (66.1%) matched
to known gene sequences and 1857 (14.1%) matched to
other ESTs. The 53 sequences (0.4%) that did not match
any known sequences were designated as putative novels.
The rest of the sequences matched genomic DNA
sequences (1957, 14.8%) and repetitive sequences (592,
4.5%, mainly Alu elements) (Table I).
Table I
General information on 13,155 ESTs from human fetal cartilage
Known gene DNA sequences ESTs Repetitive sequences Novel ESTs Total
ESTs 8696 1957 1857 592 53 13,155
Percentage 66.1% 14.8% 14.1% 4.5% 0.4% 100%
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FUNCTIONAL DISTRIBUTION OF THE KNOWN GENES
Non-redundancy analysis of the 8696 ESTs with known
gene matches resulted in a total of 2448 unique genes.
These genes were cataloged into seven categories accord-
ing to their putative functions. The functional distribution of
the known genes is shown in Table II. The largest groups in
fetal cartilage were genes lacking enough information to be
properly classified (unclassified) and genes for gene/
protein expression. They represented 22.5% (552 genes)
and 22.3% (545 genes), respectively. Genes for cell sig-
naling and metabolism were the second largest group, with
about 15.2% and 14.7% of the genes correspondingly. Cell
structure/motility group represented 10.9% of the unique
genes. The smallest groups were those for cell division
(6.7%) and cell defense (7.6%).
Furthermore, according to the EST frequency level, the
genes can be classified into three groups: highly expressed
genes (>0.05% of the EST frequency level, or at least
eight copies), moderately expressed genes (from 0.05 to
0.012%, or two to seven copies) and weakly expressed
genes (<0.012%, or only one copy)10. Only 161 (6.57%)
genes were found highly expressed, and among these
genes, over half were for the function of gene/protein
expression, and over 18% were for cell structure/motility
function. Strikingly, more than 67% of the genes were
transcripted at a low level with only one copy identified to
date (Table II).
GENES IDENTIFIED IN FETAL CARTILAGE
Table III lists some of the unique known genes (175
genes) identified in human fetal cartilage. Most of these
genes were selected because they have relatively higher
expression levels in a functional category (more than one
EST copy). One notable feature is the profile of growth
factors. Among them, insulin-like growth factor II (IGF-II)
was the most abundant, with 24 EST copies (0.18%). Along
with IGF-II, its receptor (four copies) and four different
binding proteins (IGFBP) were identified, including IGFBP2
(one copy), IGFBP3 (two copies), IGFBP4 (one copy) and
IGFBP5 (six copies). The second most abundant growth
factor was connective growth factor (CTGF) with six EST
copies. Two transforming growth factor-beta (TGF-β)
superfamily members were identified, bone morphogenetic
protein (BMP) family member BMP7 and activin. Other
identified growth factors that could play a role in cartilage
and bone formation were fibroblast growth factors (FGF2,
FGF7 and FGF13), osteoclastogenesis inhibitory factor
and stromal cell-derived factor 2 (SDF2) (Table III).
The other feature is the profile of proteases and their
regulatory factors. The most prevalent matrix metallopro-
tease (MMP) found was MMP2 (collagenase type IV, 72-
kDa or gelatinase A), which had 10 EST copies. Other
identified MMPs included MMP13 and MMP19. ADAMTS1
(a disintegrin-like and metalloprotease with thrombospon-
din type 1 motif, 1) was also found present in fetal cartilage.
Three members of the cysteine proteinase family, cathep-
sin B, cathepsin F and cathepsin K were identified as well.
More importantly, protease regulatory factors were found
present in fetal cartilage, including type 1 procollagen
C-proteinase enhancer protein and tissue inhibitor of
metalloproteinase 1 (TIMP1) (Table III).
In addition, we were able to identify some of the genes
that were, for the first time, reported in fetal cartilage. For
example, calcyclin, a calcium binding protein thought to be
involved in cell proliferation/differentiation, was found to be
highly expressed in fetal cartilage with 15 EST copies.
Some of the genes have been previously reported in
chondrocytes, but not yet in in vivo cartilage. For example,
integrin-linked kinase, which has been found in bovine
cultured chondrocytes11, was identified in fetal cartilage.
MOST ABUNDANTLY EXPRESSED GENES
The 10 most abundantly expressed genes were identi-
fied by computing their relative EST frequency levels (Table
IV). As expected, cartilage-specific matrix protein, collagen
type II alpha 1 (COL2A1), was the most abundant gene in
fetal cartilage. Moreover, among the 10 most abundant
genes, five of them represent collagens (COL1A1,
COL1A2, COL2A1, COL3A1 and COL9A1). Genes respon-
sible for protein synthesis were among the remaining most
abundant genes, including elongation factor 1-alpha and
ribosomal proteins (L10, L13A, L17 and S8), which have
also been found to be widely expressed in other tissues4,5.
GENE EXPRESSION PROFILES OF EXTRACELLULAR MATRIX
PROTEINS
In the category of cell structure/motility, a total of 1056
ESTs matched to extracellular matrix (ECM) proteins, rep-
resenting 85 unique genes (32% of the genes in this
category). Fig. 1 illustrates the expression profiles of seven
highly expressed ECM proteins (at least eight EST copies
each). As expected, most ECM protein transcripts were for
collagens (68.5%, 723/1056). Proteoglycans were the sec-
ond most abundant ECM transcripts, 9.5% (100 ESTs).
Moreover, matrilin 1 (MATN1), also known as cartilage
matrix protein, a cartilage-specific glycoprotein synthesized
by chondrocytes in a developmentally regulated manner12,
constituted 4.0% (42 ESTs) of ECM transcripts. SPARC
(secreted protein, acidic and rich in cysteine, also known as
osteonectin), a matrix protein reported in OA joints but not
in normal cartilage13, was found with a similar EST level to
that of CMP (4.0%, 42 ESTs). This was followed by
cartilage link protein (CRTL1, 20 ESTs, 19%) and fibro-
nectin (FN, 16 ESTs, 15%).
GENE EXPRESSION PROFILES OF COLLAGEN GENES
In the present study, 723 ESTs matched to 21 collagen-
coding genes, representing 13 types of collagen. The
relative EST expression profile of nine collagen genes is
shown in Fig. 2. The two most prevalent collagen genes
were COL2A1 and COL1A2, with 172 ESTs (24% of the
total collagen ESTs) and 154 ESTs (21%), respectively. The
next most abundant genes were COL1A1 and COL9A1,
representing 12% (90 ESTs) and 10% (74 ESTs), corre-
spondingly. COL3A1 constituted 7.5% of the collagen
ECM, while COL11A1, 11A2, 9A3 and 9A2 represented 6.4,
4.7, 3.6 and 2.9%, respectively. The rest of the identified
collagen genes were less than 10 EST copies (<1.5% of
the total collagen ESTs).
GENE EXPRESSION PROFILE OF PROTEOGLYCAN GENES
Sixteen individual proteoglycan genes were identified in
fetal cartilage. Seven of them were either highly or moder-
ately expressed. Fig. 3 illustrates their expression profile.
The three most abundant proteoglycan genes were glypi-
can 3 (GPC3, 15 ESTs, 15% of proteoglycan ESTs),
decorin (DCN, 14 ESTs, 14%) and aggrecan (AGG, 14
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Metabolism Unclassified Total Percentage of
total
Highly 6 3.70% 16 9.32% 28 18.01% 4 2.48% 92 57.14% 9 5.59% 6 3.73% 161 6.57
Moderately 44 7.17% 90 14.68% 81 13.38% 51 8.32% 141 23% 104 16.80% 102 16.64% 613 25.03
Weakly 114 6.74% 267 15.94% 158 9.55% 131 7.82% 312 18.63% 248 14.81% 444 26.51% 1674 67.66











List of 175 genes identified in human fetal cartilage
Cell division (34 genes) Accession no. Copy no.
Calcyclin (=S100 calcium-binding protein A6) Hs.275243 15
Cell death-regulatory protein GRIM19 Hs.279574 4
Cell division cycle 42 (GTP binding protein, 25 kDa) Hs.146409 4
Cyclin I Hs.79933 4
Defender against cell death 1 (DAD1) NM_001344.1 3
Nerve growth factor receptor (TNFRSF16) associated protein 1 Hs.17775 3
Transforming growth factor beta-induced, 68 kDa (TGFβI) Hs.118787 3
Death-associated protein 3 (DAP3) Hs.159627 2
Basic transcription factor 2 p44 (btf2p44) gene U80017.1 2
Apoptosis related protein APR-1 AF143235.2 2
Chromosome condensation 1 Hs.84746 2
Cyclin D2 Hs.75586 2
Cell death suppressor (WA1) AF000267 1
Programmed cell death 6 interacting protein (PDCD6IP) Hs.9663 1
Programmed cell death 6 (PDCD6) NM_013232.1 1
Programmed cell death 5 (PDCD5) NM_004708.1 1
Brain cellular apoptosis susceptibility protein (CSE1) AF053641 1
Apoptosis inhibitor (IEX-1L) gene AF071596.1 1
CUG triplet repeat, RNA-binding protein 2 (CUGBP2) NM_006561.1 1
Apoptosis inhibitor survivin gene U75285.1 1
APG5 (autophagy 5, S. cerevisiae)-like (APG5L) NM_004849.1 1
Caspase 3, apoptosis-related cysteine protease (CASP3) NM_004346.1 1
TNF receptor-associated factor 2 (TRAF2) Hs.200526 1
Tumor necrosis factor type 1 receptor associated protein NM_016292.1 1
Tumor necrosis factor receptor superfamily, member 1A M58286 1
CDC37 cell division cycle 37 homolog (S. cerevisiae) U43077 1
Proliferating cell nuclear antigen Hs.78996 1
Cyclin D1 (PRAD1: parathyroid adenomatosis 1) X59798 1
CDC14 cell division cycle 14 homolog A (S. cerevisiae) AF000367 1
Cyclin B1 M25753 1
Cyclin-dependent kinase inhibitor 1A U09579.1 1
Cyclin T2 NM_001241.1 1
TGF-beta inducible early protein (TIEG) U21847 1
RAD9 (S. pombe)(=cell cycle checkpoint control protein) NM_004584.1 1
Cell signaling/communication (52 genes)
Insulin-like growth factor II (IGF-II) Hs.349109 24
Guanine nucleotide binding protein (G protein) (GNB2L1) NM_006098.1 21
Chondromodulin I precursor (CHM-I) NM_007015.1 15
Receptor activity modifying protein 1 (Ramp1) AJ314840 14
Thymosin beta-4 (TMSB4X) M17733 14
Syntaxin 4 binding protein UNC-18c (UNC-18c) AF032922.1 10
Guanine nucleotide binding protein (G protein) (GNAS1) NM_000516.2 9
Thymosin beta-10 S54005 9
Calumein (Calu) AF013759 8
Calmodulin 1 (phosphorylase kinase, delta) (CALM1) NM_006888.1 7
Connective tissue growth factor (CTGF) U14750 6
Insulin-like growth factor binding protein 5 (IGFBP5) gene L27556.1 6
Insulin-like growth factor II receptor Y00285 4
Platelet-derived growth factor receptor alpha (PDGFRA) M21574 4
Alpha E-catenin (CTNNA1) gene AF102803.1 3
Endothelial differentiation-related factor 1 (EDF1) NM_003792.1 3
Heparin-binding neurite outgrowth promoting factor S60110 3
Integrin-linked kinase (ILK) U40282 3
Interleukin 11 receptor, alpha (IL11RA) NM_004512.1 3
Novel growth factor receptor M64347 3
Vascular endothelial growth factor (VEGF) AF024710.1 3
Voltage-dependent anion channel isoform 1 (VDAC) L06132 3
Beta-catenin X87838 2
ERK activator kinase (MEK2) L11285 2
Fibroblast activation protein, alpha; seprase (FAP) NM_004460.1 2
Fibroblast growth factor 7 (keratinocyte growth factor) (FGF7) NM_002009.1 2
Fibroblast growth factor receptor (FGFR-4) X57205 2
GTP binding protein=RAN, member RAS oncogene family (ARA24) AF054183 2
GTPase activating protein (rap1GAP) M64788 2
GTP-binding protein (HSR1)=GNL1 L25665 2
Insulin-like growth factor binding protein-3 X64875 2
Interferon gamma receptor accessory factor-1 (AF-1) U05877 2
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Table III
Continued
Cell division (34 genes) Accession no. Copy no.
Latent transforming growth factor beta binding protein 1 (LTBP1) NM_000627.1 2
Macrophage migration inhibitory factor (MIF) NM_002415.1 2
Osteoclastogenesis inhibitory factor AB008822 2
RAB34, member RAS oncogene family NM_031934.1 2
RAN, member RAS oncogene family Hs.10842 2
Retinoic acid-binding protein II (CRABP-II) M97814 2
Rho guanine nucleotide exchange factor (GEF) 1 (ARHGEF1) NM_004706.1 2
Serine/threonine kinase KPM AF207547.1 2
Activin A receptor, type I (ACVR1) NM_001105.1 1
Activin beta-C chain X82540 1
Stromal cell-derived factor 2 (SDF2) D50645 1
Bone morphogenetic protein 7 (osteogenic protein 1) (BMP7) NM_001719.1 1
Fibroblast growth factor 13 (FGF13) NM_004114.1 1
Fibroblast growth factor 2 (basic) (FGF2) NM_002006.1 1
Fibroblast growth factor receptor 3 A113 (FGFR3) XM_044120.1 1
Fibroblast growth factor receptor (N-sam) X66945 1
Insulin-like growth factor binding protein (IGFBP-2) X16302 1
Insulin-like growth factor binding protein 4 (IGFBP4) M62403.1 1
Latent transforming growth factor beta binding protein 2 (LTBP2) NM_000428.1 1
Mitogen-activated protein kinase 7 (MAPK7) NM_002749.1 1
Cell structure/motility (22 genes)
SPARC (secreted protein, acidic, rich cysteine) Hs.111779 42
Matrilin 1 (MATN1) Hs.150366 42
Cartilage link protein (CRTL1) U43328.1 20
Fibronectin (FN) Hs.287820 16
Collagen type XII, alpha 1 (COL12A1) NM_004370.4 10
Fibromodulin (FMOD) NM_002023.2 8
Matrilin-3 (MATR3) Y13341 7
Elastin (ELN) U62292 7
Matrix Gla protein (MGP) X53331 6
Microfibril-associated glycoprotein (MFAP2) U19718 4
Chondroadherin (CHAD) U96769 4
Clathrin, heavy polypeptide-like 2 (CLTCL2) NM_004859.1 4
Filamin (FLNB) AF191633.1 4
Integral membrane protein 2A (ITM2A) NM_004867.1 4
Glypican 1 (GPC1) NM_002081.1 3
Actin binding protein ABP620 AB029290.1 3
Cartilage oligomeric matrix protein (COMP) NM_000095.1 2
Vacuolar protein sorting 28 (yeast) (VPS28) NM_016208.1 2
Microtubule-associated protein 4 (MAP4) NM_002375.1 2
Glypican-5 (GPC5) U66033 1
Glypican-6 (GPC6) AF105267.1 1
Cartilage intermediate layer protein, CILP AB022430.1 1
Cell/organism defense (11 genes)
Heat shock protein 90 (=HSP90) AF203815.1 11
XPB/ERCC-3-like protein Y17148.1 6
Annexin A6 Hs.118796 5
Beta-2 microglobulin gene (B2M) AF072097.1 5
Glutathione S-transferase P1c (GSTp1c) U62589.1 4
Superoxide dismutase 1 (SOD1) Hs.75428 3
Peroxiredoxin 1 (PRDX1) NM_002574.1 3
Xeroderma pigmentosum group E UV-damaged DNA binding factor (DDB1) U32986.1 3
RAD21 homolog (S. pombe) X98294 3
Scrapie responsive protein 1 (SCRG1) NM_007281.1 3
Metallothionein 1L (MT1L) NM_002450.1 2
Gene/protein expression (29 genes)
Ribosomal protein L9 U09953 47
Ribosomal protein L7 X52967 45
Ribosomal protein S20 (RPS20) NM_001023.1 42
Ribosomal protein S8 (RPS8) NM_001012.1 42
Elongation factor 2 X51466 16
Osteoblast-specific factor 2 (OSF-2os) D13666.1 15
Eukaryotic translation initiation factor 3 (EIF3S6) NM_001568.1 12
MMP2 (collagenase type IV, 72 kDa) Hs.111301 10
Glutaminyl-tRNA synthetase (QARS) NM_005051.1 8
Carboxypeptidase E (CPE) NM_001873.1 6
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ESTs, 14%). Proteoglycan 4 (also known as megakaryo-
cyte stimulating factor, MSF), lumican (LUM), syndecan 2
(SDC2) and fibromodulin were expressed at a similar level,
about 8–10% of the total proteoglycan ESTs.
Discussion
The EST approach used in this study is a potent method
for identifying and characterizing both known and novel
genes in a given tissue. Over the past few years, cDNA
libraries have been prepared from many tissues and cell
lines, from which a large number of ESTs have been
obtained and studied4–7. However, there have been no
reports on large-scale generation of ESTs from human fetal
cartilage. In the present study, we applied the EST
approach to fetal cartilage, and analyzed 13,155 ESTs
obtained from a human fetal cartilage cDNA library.
With respect to overall EST distribution (i.e. known gene
matches, EST matches and novel), the results from fetal
cartilage were similar to those obtained from other tissues.
The known gene matches was the largest group of the
ESTs, as found in other EST studies, whereas the novel
transcripts only represented a small portion of the ESTs4–7.
However, we identified fewer novel clones (53 clones,
0.4%), as compared to other previous EST reports
(>10%)4–7. This is mainly due to the recent global efforts in
sequencing the human genome and in analyzing gene
expression in different tissues. These efforts have resulted
and continue to account for a dramatic increase in the
Table III
Continued
Cell division (34 genes) Accession no. Copy no.
Nuclear protein SDK3 Y10351 6
Poly (A)-binding protein (PABP) U68105 6
Cathepsin K (CTSK) NM_000396.1 5
Calpain-like protease (CANPX) NM_014289.1 4
General transcription factor 2-I (GTF2I) AF038968 4
HTRA serine protease (PRSS11) Hs.75111 4
Zinc finger protein 262 (ZNF262) AB007885 4
Zinc finger protein (MAZ) M94046 4
Cathepsin B (CTSB) L22569 3
Procollagen C-proteinase enhancer protein, type 1 AB008549 3
Cathepsin F (CATSF) AF071749 2
Matrix metalloproteinase 15 (membrane-inserted) (MMP15) NM_002428.1 2
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) Hs.41270 2
Tissue inhibitor of metalloproteinase 1 (TIMP1) Hs.5831 2
Tissue inhibitor of metalloproteinase 3 (TIMP3) NM_000362.1 2
ADAMTS1 (a disintegrin-like metalloprotease with thrombospondin type 1 motif, 1) AF207664 1
Matrix metalloproteinase 13 (collagenase 3) (MMP13) NM_002427 1
Matrix metalloproteinase 19 (MMP19) NM_002429 1
Bone morphogenetic protein 1 (BMP1) Hs.1274 1
Metabolism (13 genes)
Enolase 1, alpha (ENO1) NM_001428.1 16
Dolichyl-phosphate beta-glucosyltransferase (ALG5) AF102850.1 14
Annexin A2 (ANXA2) NM_004039.1 14
Annexin A5 (ANXA5) NM_001154.2 9
Lysyl oxidase U22384 6
High density lipoprotein binding protein (HBP) M64098 5
Phosphoglycerate mutase (PGAM-B) J04173 5
78 kDa glucose-regulated protein (GRP78) M19645.1 5
ADP/ATP translocase J03592 5
Lysyl hydroxylase M98252 2
Aspartyl-tRNA synthetase (DARS) NM_001349.1 2
6-Phosphogluconolactonase (PGLS) NM_012088.1 2





Integral membrane protein 2B (ITM2B) NM_021999.1 10
Antigen NY-CO-33 AF039698.1 8
Fau X65923 7
PRO2640 AF116710.1 6
1–8U gene from interferon-inducible gene family X57352.1 6
Tis11d gene U07802 5
HSPC016 Hs.171774 5
Sin3-associated polypeptide (SAP18) AF153608 4
KIAA0076 D38548 3
KIAA0107 D14663 3
GABA (A) receptor-associated protein-like 2 (GABARAPL2) NM_007285.2 2
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deposition of genomic DNA and EST sequences in the
public databases as reflected by our fetal EST distribution
(14.8% matched genomic DNA sequences and 14.1%
matched other ESTs). On the other hand, these 53 novel
clones identified in fetal cartilage could be of importance in
cartilage development and will be further investigated.
The presence of repetitive sequences has been reported
by many researchers4–7. Generally, repetitive elements do
not occur in protein-coding regions. Their presence could
be the result of repetitive sequences (e.g. Alu elements) in
the 3′ untranslated regions, transcription of independent
repetitive elements, unspliced precursor RNA and genomic
DNA contamination of the cDNA library4. The content of
these repetitive sequences varies greatly from cDNA
libraries (0–23.5%)4. Our fetal cartilage cDNA library only
contained 4.5% repetitive sequences.
Functional categorization of the known genes reflects
general differences in gene expression between differ-
ent tissues. For instance, there was a larger portion of
unclassified genes in cartilage (22.5%) than that in other
tissues, such as fetal heart (15.6–17.5%)5. This could be
due, at least in part, to our lack of a comprehensive
understanding of the genes involved in cartilage develop-
ment. Alternatively, the large numbers of hypothetical pro-
teins generated by recent high throughput genome
sequencing efforts may have contributed to this discrep-
ancy. Moreover, there were more genes involved in
‘metabolism’ in fetal heart (30%) compared with fetal carti-
lage (14.7%). This suggests that fetal cartilage has a
lower metabolic rate than that of fetal heart5.
Since ESTs represent the genes expressed in a given
tissue, the EST profile should feature the specificity of the
tissue analyzed. The tissue specificity of this fetal cartilage
cDNA library was well reflected by its two distinctive EST
profile features. One feature was that ESTs for collagen
constituted the majority (68.5%) of all ESTs matched for
ECM. The other was that collagen type II alpha 1 gene was
the most abundant gene of all matched known genes. This
latter feature was also noted in the study on mouse growth
plate14. However, the relative redundancy level of collagen
type II alpha I gene in mouse growth plate (13%, 55/410)
was much higher than that found in human fetal cartilage
(1.3%, 172/13,155). Since mouse growth plate is from
immature cartilage as opposed to fetal cartilage, it should
be more differentiated and is likely to have more type II
Table IV
Ten most abundantly expressed genes
Gene name Accession no. Copy Percent
1 Collagen type II, alpha
1 (COL2A1)
J00116.1 172 1.28
2 Collagen type I, alpha 2
(COL1A2)
NM_000089.1 154 1.15
3 Elongation factor 1
alpha 1 (EEF1A1)
NM_001402.1 150 1.12
4 Collagen type I, alpha 1
(COL1A1)
X06269 90 0.67
5 Collagen type IX, alpha
1 (COL9A1)
NM_001851.1 74 0.55






8 Ribosomal protein L37a
(RPL37a)
L22154 56 0.42
9 Collagen type III, alpha
1 (COL3A1)
X06700 54 0.40
10 Ribosomal protein L10
(RPL10)
P27635 53 0.40
Fig. 1. Relative expression levels of seven types of ECM proteins
in human fetal cartilage. EST numbers matched to each type of
ECM were summed. EST frequency was then calculated by
dividing the EST copy number of each ECM into the total number
of ECM ESTs (n1056). COL, collagens; PG, proteoglycans;
MATN1, matrilin 1; SPARC, secreted protein, acidic and rich
in cysteine (osteonectin); CRTL1, cartilage link protein 1; FN,
fibronectin.
Fig. 2. Relative expression levels of nine collagen genes in human
fetal cartilage. Relative EST frequency level was calculated by
dividing the EST copy number of each collagen gene into the total
number of collagen ESTs (n723).
Fig. 3. Relative expression levels of six proteoglycan genes in
human fetal cartilage. Relative EST frequency level was calculated
by dividing the EST copy number of each proteoglycan gene into
the total number of proteoglycan ESTs (n92). GPC3, glypican 3;
DCN, decorin; AGG, aggrecan; PG4, proteoglycan 4; LUM,
lumican; SDC2, syndecan 2; FMOD, fibromodulin.
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collagen where fetal cartilage is likely to have a mixture of
types I and II collagen. Moreover, the discrepancy could be
partly due to sampling size, as a relatively small number of
ESTs were studied in the mouse growth plate (608 total
ESTs, with 410 ESTs matched to known genes)14.
Using this EST approach, we were able to demonstrate
several interesting aspects of the ECM in human fetal
cartilage. One feature of the collagen EST profile was the
relative EST abundance for collagen type I. Although the
presence of collagen type I at early stages of chondrogen-
esis has been previously established by immunolocaliz-
ation, its relative expression level, time course and
mechanisms underlying its eventual elimination in mature
cartilage are not yet clear15,16. In human newborn femoral
head, collagen type I was still found to be synthesized by
articular surface chondrocytes16. In the present study, our
EST data showed that collagen type I was not only
expressed in fetal cartilage, but also redundantly
expressed at levels comparable to that of collagen type II.
Since the library was constructed from pooled cartilage
samples over a relatively large time frame (8–12 weeks),
this could be one of the reasons that we observed strong
type I collagen gene expression. However, the level of
collagen type I found could also be due in part to other
tissue contaminations, such as perichondrium and primary
spongiosa, though precaution was taken at the time of
tissue collection. Moreover, more transcripts of COL1A2
(154 EST copies) than COL1A1 (90 copies) were identified.
Since collagen type I is synthesized as a heterotrimer
which is composed of two chains of COL1A1 and one chain
of COL1A216, one would expect to find more COL1A1
transcripts than COL1A2. One possible explanation for this
discrepancy is that the transcriptional activity of the
COL1A2 gene is enhanced by the co-presence of two
dinucleotide repeats (poly (dC-dA) and poly (dC-dG))17.
The other feature that we identified was 13 different types
of collagen in fetal cartilage. Some of the collagens have
been known to be expressed in fetal cartilage, such as
collagen types IX and XI, two cartilage-specific collagens
that are consistently found with type II collagen18. Impor-
tantly, to our knowledge, some of the collagens were, for
the first time, identified in human fetal cartilage. For
instance, collagen XII, a fibril-associated collagen that has
been previously suggested as a component of cartilage
and has been found to be present in the joint interzone on
embryonic day 16 in rat forelimb19 was identified in our
study. We observed 10 EST copies of collagen type XII
(Table III), suggesting its relatively high level presence in
human fetal cartilage.
Besides the collagen genes, we also noted an interesting
aspect of proteoglycan genes. We found that glypican 3
was highly expressed in fetal cartilage (15 ESTs, 0.11%).
Glypican 3 is one of six glypicans identified in vertebrates.
Glypicans represent one of the two cell surface heparan
sulfate proteoglycan families, the other being the syndecan
family20. They have been suggested to be important in
developmental situations due to their ability to bind and
modulate the activities of a range of morphogens and
growth factors such as IGFs, FGFs and BMPs20. Glypican
3 is of particular importance since it is the only member
whose mutation causes the Simpson–Golabi–Behmel syn-
drome (SGBS), a rare X-linked disorder characterized by
pre- and postnatal overgrowth of multiple tissues and
organs, and multiple visceral and skeletal abnormalities21.
It is suggested that glypican 3 plays a critical role in fetal
development. Though the in vivo mechanism of its func-
tions is not yet clear, the proposed mechanism is that
glypican 3 exerts an active role through regulating IGF-II
activity20,21. The fact that IGF-II was the most abundant
growth factor identified in fetal cartilage suggests that
both glypican 3 and IGF-II are important in fetal cartilage
development. Other glypicans identified include glypicans
1, 5 and 6, but at much lower levels than glypican 3
(Table III).
In addition to the ECM features of this cDNA library,
another interesting observation was that of IGF-II and its
binding proteins. IGF-II has been suggested to play an
important role in fetal development22. A probable role in
chondrogenesis and osteogenesis is suggested by its
presence in chondrogenic regions of murine models23,24.
Correspondingly, we found that IGF-II was the most
abundant growth factor in human fetal cartilage. IGF-II has
also been recently listed as one of the most frequently
expressed genes by human fetal epiphyseal chondrocytes
(20–24 weeks) cultured under differentiated conditions25.
The IGFBPs identified in this study have also been previ-
ously localized to chondrogenic regions24,26. Our data
support the view that the IGF system is integrally involved
in early cartilage and bone development.
The identification of BMP1 in fetal cartilage is also
very interesting. BMP1 is also known as procollagen
C-proteinase (PCP) and is required for cartilage and bone
formation. PCP cleaves the C-terminal propeptides of pro-
collagens I, II and III, and its enzyme activity is enhanced
by the procollagen C-proteinase enhancer protein27. The
coexistence of BMP1 and procollagen C-proteinase
enhancer protein (Table III) suggests autocrine regulation
for mature collagen production in fetal cartilage.
Many ESTs expressed in fetal cartilage were either not
observed or had markedly different expression profiles
compared with recently reported EST data obtained from
human normal and osteoarthritic cartilages28. For example,
none of the 10 most abundant genes found in fetal cartilage
were among the top 20 abundant genes in normal and
osteoarthritic cartilages28. This implies that the gene
expression pattern of cartilage may be quite different be-
tween fetal and mature adult stages. Despite the differ-
ences in EST expression levels, most of the matrix proteins
reported in adult cartilage were also found in fetal cartilage,
such as COL1A1, COL1A2, COL2A1, decorin, aggrecan,
COMP, fibronectin and fibromodulin. Among other genes
that were shared by fetal, normal and OA cartilages,
translationally controlled tumor protein, connective tissue
growth factor (CTGF), zinc finger protein 216 and tissue
inhibitor of metalloproteinase 3 (TIMP3) were included28.
Although we have identified many genes expected to be
present in fetal cartilage, there are some genes that are
expected but have not been identified to date (e.g. hyalu-
ronan synthetases, TGF-β1 and IGF-I). This is likely
because a larger EST sample size will be required in
order to identify the complete repertoire of genes that are
expressed by fetal chondrocytes. Thus, the absence of a
gene by cDNA sequencing does not prove the lack of this
gene in fetal cartilage. The genes that were expressed at
low level (only one copy) should be ideally confirmed by
other means of study, such as in situ hybridization and
RT-PCR. However, due to the scarcity of human fetal
tissue, we have not had the opportunity to verify the
presence of these genes through other means. Another
limitation of this work is that the tissue used for this study
may contain other types of developing cartilage besides
articular cartilage, such as cartilage destined to ossify and
possibly growth plate cartilage. This should be taken into
consideration for data interpretation.
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The current study provides a global molecular profile of
human fetal cartilage. The complete list of all identified
known genes has been made available by ChondroGene
Inc., through their website at http://www.chondrogene.com
as well as having been deposited in GenBank. Genes of
interest can be identified and targeted for further research.
Novel ESTs identified through this effort are currently
under further investigation for their full-length sequencing,
specific tissue distribution and functions in cartilage.
Moreover, the PCR products of these EST clones (known
and novel) have been used as templates for the generation
of microarrays for further research (unpublished work).
Probing these arrays with cartilage samples from different
developmental or disease stages will help define differen-
tially expressed genes. Identification of these genes can
enhance our understanding of the mechanisms and path-
ways that underlie cartilage development, injury and repair.
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